Product Description
Mechanisms of Action: Angiogenesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Ophthalmic
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Genaera
Company Location: PLYMOUTH MEETING PA 19462
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Choroidal Neovascularization|Macular Degeneration|Wet Macular Degeneration
Phase 2: Macular Degeneration|Wet Macular Degeneration|Retinal Neovascularization|Macular Edema|Diabetic Retinopathy|Choroidal Neovascularization|Prostate Cancer|Ovarian Cancer|Retinal Vein Occlusion
Phase 1: Amyotrophic Lateral Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12619000375156 | P1 |
Completed |
Amyotrophic Lateral Sclerosis |
2018-11-06 |
|
| MAKO | P3 |
Unknown status |
Macular Degeneration |
2017-12-01 |
|
| OHR-1501 | P2 |
Withdrawn |
Wet Macular Degeneration |
2016-04-01 |
|
| Ohr-005 | P2 |
Withdrawn |
Diabetic Retinopathy|Macular Edema |
2015-09-01 |